In determining the quality control limits for the Clinical Laboratory Standards Institute-recommended quality control organisms with tigecycline, a number of inconsistencies in the results were encountered that appeared to be related to the age of the Mueller-Hinton broth II. This study was performed to examine the effect of medium age and supplementation with Oxyrase on the activity of tigecycline using a large number of clinical isolates.
In determining the quality control limits for the Clinical Laboratory Standards Institute-recommended quality control organisms with tigecycline, a number of inconsistencies in the results were encountered that appeared to be related to the age of the Mueller-Hinton broth II. This study was performed to examine the effect of medium age and supplementation with Oxyrase on the activity of tigecycline using a large number of clinical isolates.
Tigecycline (GAR-936), the 9-t-butylglycylamido derivative of minocycline (14) , is the first in class of the "glycylcycline" antimicrobial agents to enter into phase 3 clinical trials. Tigecycline binds to the 30S ribosomal subunit, blocking entry of amino-acyl tRNA molecules into the A site of the ribosome, inhibiting protein translation in bacteria (11) .
During the establishment of the quality control (QC) ranges for tigecycline, inconsistencies were noted in the MIC limits obtained in various studies. Further investigative studies revealed that discrepancies between fresh Mueller-Hinton broth II (MHB) and aged MHB were due to acceleration of the oxidative inactivation of tigecycline (3) . Previous studies have shown that the concentration of dissolved oxygen in the broth media could be controlled by the addition of a biocatalytic oxygen-reducing reagent (Oxyrase) (3, 12, 13) . This study was undertaken to evaluate the in vitro activity of tigecycline against recent clinical isolates in fresh MHB, aged MHB, and aged MHB supplemented with Oxyrase.
Routine clinical isolates were collected in the United States and Canada between 1990 and 2004. Identification of each culture was done as previously described (10) . The extendedspectrum ␤-lactamase (ESBL) and AmpC-producing Klebsiella pneumoniae strains used were well-characterized strains expressing a variety of ␤-lactamase enzymes and have all been described previously (2) .
MICs were determined by the broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (9) . Frozen microdilution panels were prepared by Trek Diagnostic Systems (Cleveland, OH) using fresh MHB (Ͻ12 h old), aged MHB (Ͼ7 days old), and aged MHB with 2% Oxyrase for broth (Oxyrase, Inc., Mansfield, OH) for tigecycline. For streptococcal isolates the MHB contained 5% lysed horse blood, and Haemophilus test medium broth was used for Haemophilus spp. The concentration of the final inoculum was 1 ϫ 10 5 to 5 ϫ 10 5 CFU/ml in a 100-l final volume. The plates were incubated for 18 to 24 h at 35°C in ambient air.
The in vitro antibacterial activities of tigecycline in fresh MHB, aged MHB, or aged MHB supplemented with Oxyrase, as well as comparative antibacterial agents, against recent clinical isolates is displayed in Tables 1 and 2 . Against most non-Proteeae enteric bacilli, when tigecycline was tested in fresh MHB, MICs were generally 1 dilution lower than when tested in aged media (MICs at which 90% of strains are inhibited [MIC 90 s], 0.25 to 1 and 0.5 to 2 g/ml, respectively) ( Table 1) . Supplementation of the media with Oxyrase gave similar results to that obtained with fresh media (MIC 90 s, 0.25 to 1 g/ml). When comparing the individual tigecycline MICs (Fig. 1) , 38% of the isolates tested had MICs 2 or more dilutions higher in aged MHB when compared to fresh MHB. In contrast, only 1.8% of the isolates tested in Oxyrase MHB had a decrease of two or more dilutions in tigecycline activity when compared to fresh MHB. In general, when tested in fresh MHB, tigecycline showed activity similar to that of imipenem (MIC 90 s, 0.25 to 2 g/ml) but was less active than levofloxacin (MIC 90 s, Յ0.06 to 1 g/ml). It is of particular interest that tigecycline, with a MIC 90 of 2 g/ml, was at least 4 twofold dilutions more active than any of the other antimicrobial agents tested against the AmpC-producing K. pneumoniae strains.
Tigecycline has been shown to be intrinsically less active against the Proteeae, including Proteus spp., Providencia spp., and Morganella morganii (5, 7, 10) , and these results were confirmed in this study ( Table 1 ). The MIC 90 s for tigecycline tested in the Oxyrase-supplemented MHB were similar to those obtained in fresh media and were approximately 1 dilution lower than the results obtained in aged MHB (MIC 90 s, 2 to 4, 2 to 8, and 4 to 8 g/ml, respectively). Tigecycline tested in fresh MHB was less active than levofloxacin (MIC 90 s, Յ0.06 g/ml), similar to imipenem (MIC 90 s, 4 to 8 g/ml), and more active than minocycline (MIC 90 s, 16 to 32 g/ml). There were no strains of Proteus spp., and M. morganii was encountered in this collection with a tigecycline MIC of Ͼ8 g/ml. 
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As shown in Table 1 a difference in activity between fresh and aged MHB was not observed when tigecycline was tested against the nonfermentative gram-negative bacilli when comparing MIC 90 s (2 to 16 g/ml). In fresh MHB, tigecycline was at least 2 dilutions more active than the comparative antimicrobial agents against Acinetobacter baumannii (MIC 90 , 2 g/ml). When tested in Oxyrase-supplemented MHB, tigecycline was consistently 1 dilution more active than in aged or fresh MHB (MIC 90 s, 1 to 8 g/ml). The effect of Oxyrase on the growth of these organisms has not been reported and may warrant further investigation. 
Tigecycline demonstrated potent in vitro activity against all staphylococcal strains tested in fresh media (MIC 90 s, 0.25 to 0.5 g/ml) ( Table 2 ). Tigecycline tested in fresh MHB was twoto fourfold more active than in aged MHB (MIC 90 s, 0.5 to 1 g/ml) and similar to Oxyrase-supplemented MHB (MIC 90 s, 0.12 to 1 g/ml). Against the more resistant strains (methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and Staphylococcus haemolyticus), tigecycline was more active than imipenem, levofloxacin, and ceftriaxone (MIC 90 s, 32 to Ͼ128 g/ml).
When tested in fresh MHB, tigecycline showed good in vitro activity, with MIC 90 s of 0.06 to 0.12 g/ml against enterococcal strains ( Table 2, Fig. 2) . The activity of tigecycline tested in fresh MHB exceeded that of aged MHB by 2 to 4 dilutions and was equal to or more active than results obtained in Oxyrasesupplemented MHB (MIC 90 s, 0.5 to 1 and 0.06 to 0.5 g/ml, respectively). The comparison of individual MICs in Fig. 2 demonstrates the improved activity of tigecycline when tested in fresh MHB. Tigecycline tested in fresh MHB exceeded the activity of the comparative antibacterial agents by at least 4 twofold dilutions against all strains and by at least 7 twofold dilutions against vancomycin-resistant strains. The true activity demonstrated by tigecycline in fresh MHB against the enterococcal strains may account for the better than expected therapeutic efficacy previously demonstrated in rat models of experimental enterococcal endocarditis (6, 8) . The Clinical Laboratory Standards Institute has approved QC ranges for tigecycline using fresh MHB, and this methodology is now considered to be the reference method for MIC testing with tigecycline (4). This study looked at the effect of medium age and the addition of Oxyrase against Ͼ2,600 clinical isolates to determine the effect of these various conditions on a broad population of relevant clinical organisms.
The results of this study confirm the increased activity demonstrated by tigecycline in fresh media against a large and diverse population of bacteria. Overall, when compared to prior published data (1, 5, 7, 10) , tigecycline was generally 1 to 2 dilutions more active when tested in fresh MHB. In addition, the use of Oxyrase to reduce the oxygen content in aged media is a viable alternative to using fresh media. 
